Skip to content

Clinical research on the adjuvant treatment of type 2 diabetes with Morus alba leaf and Momordica charantia tablets

Clinical research on the adjuvant treatment of type 2 diabetes with Morus alba leaf and Momordica charantia tablets

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122220
Enrollment
Unknown
Registered
2026-04-10
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Trial Group:Conventional antidiabetic drugs + mulberry bitter melon tablet candy 0.5g per dose, three times daily
Control Group:Conventional antidiabetic drugs

Sponsors

South China Hospital of Shenzhen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 70; 2.Diagnosed with type 2 diabetes (meeting WHO criteria); 3.Sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Severe liver and kidney dysfunction; 2.Infants and young children, pregnant women, and lactating women; 3.There has been a history of diabetic ketoacidosis or severe hypoglycemia within the last 3 months; 4.The researchers determined that there were other conditions that made participation in the trial unsuitable (such as mental disorders, communication disorders, life expectancy less than one year, etc.); 5.People who are allergic to the components of Morus alba leaf and Momordica charantia; 6.Participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Blood glucose two hours after a meal;Glycated hemoglobin;Fasting blood glucose;

Secondary

MeasureTime frame
Hepatic and renal function;Overall incidence of adverse events;

Countries

China

Contacts

Public ContactLiu Nan

South China Hospital of Shenzhen University

nanliu@szu.edu.cn+86 755 21583851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026